Related Experiment Videos
Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA
L Yen1, S M Strittmatter, R G Kalb
1Department of Neurology, Yale University, School of Medicine, New Haven, CT, USA.
Insights
Researchers developed catalytic DNA to degrade Huntington's disease (HD) mRNA, reducing toxic mutant HD protein levels in cells. This offers a potential therapeutic strategy for HD by targeting the disease-causing mRNA.
Area of Science:
- Molecular Biology
- Neuroscience
- Biochemistry
Background:
- Huntington's disease (HD) results from CAG triplet expansion in the HD gene, leading to selective neuronal loss.
- The exact molecular mechanisms of neuronal death in HD are unclear, but a gain-of-function by mutant HD protein is suspected.
Purpose of the Study:
- To investigate the potential of catalytic DNA (DNAzyme) for degrading Huntington's disease mRNA.
- To assess the efficacy of sequence-specific mRNA cleavage in reducing mutant HD protein expression.
Main Methods:
- Utilized catalytic DNA (oligodeoxynucleotides with RNA-cleaving activity) designed to target HD mRNA.
- Demonstrated sequence-specific cleavage of HD mRNA in mammalian cells.
- Quantified the reduction in mutant HD protein expression post-treatment.
Main Results:
- Successfully demonstrated the first effective destruction of Huntington's disease mRNA using catalytic DNA.
- Achieved sequence-specific cleavage of HD mRNA, leading to a significant decrease in mutant HD protein levels.
- Validated catalytic DNA as a tool for reducing cellular toxicity associated with mutant HD protein.
Conclusions:
- Catalytic DNA effectively cleaves Huntington's disease mRNA in a sequence-specific manner.
- This approach significantly reduces mutant HD protein expression in mammalian cells.
- Developed catalytic DNAs show promise as research tools and potential therapeutics for Huntington's disease.
Abstract:
The selective loss of neurons in Huntington's disease (HD) is caused by the abnormal expansion of the CAG triplet (>36 repeats) of the HD gene. Although the molecular events that lead to neuronal death are not clear, it is most likely that mutant HD protein operates through a "gain-of-function" mechanism. One possible therapeutic approach that does not require definition of the toxic mechanism(s) involves reduction in the levels of mutant HD protein by decreasing the quantity of translatable HD mRNA. In this report, we demonstrate the first effective destruction of the HD mRNA, using a catalytic DNA--an oligodeoxynucleotide with RNA-cleaving enzymatic activity. We show that the cleavage of HD mRNA by the catalytic DNA occurs in a sequence-specific manner, and leads to significant reduction of HD protein expression in mammalian cells. The catalytic DNAs we have developed are a valuable research tool for studying HD, and may have the therapeutic potential of reducing cellular toxicity caused by mutant HD protein.